Advanced Prostate Cancer VL

Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce

Details
Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

Details
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...

Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore

Details
Neal Shore discusses the ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment strateg...

Biochemical Recurrence in Patients with Prostate Cancer after Primary Definitive Therapy: Next-Generation Imaging and Treatment Based on Risk Stratification - Beyond the Abstract

Details
Historically, conventional imaging techniques have been used for the assessment of clinical progression in biochemical recurrence (BCR). However, these imaging technologies have limited sensitivity at low PSA values (<10 ng/mL). Next-generation imaging (NGI) technologies may overcome the sensitivity limitations associated with low PSA values and offer improved diagnostic accuracy for identifying B...

COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis

Details
Alicia Morgans, Mark Markowski, and Emmanuel Antonarakis discuss research on high-dose testosterone therapy for metastatic castration-resistant prostate cancer, inspired by Sam Denmeade's paradoxical approach. The COMBAT trial, a phase II study, explored the efficacy of combining bipolar androgen therapy (BAT) with the immune checkpoint inhibitor nivolumab, revealing notable PSA response rates and...

PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik

Details
Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to guid...

CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal

Details
Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressed on one novel hormonal therapy (NHT). This trial, which focuses on patients with extrapelvic soft tissue metastasis, has shown a significant reduction in the ri...

BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George

Details
Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial's innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in patient...

Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt

Details
Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...

ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg

Details
Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at determining the optimal treatment sequence for metastatic prostate cancer and identifying predictive biomarkers for treatment efficacy. Unique to ProBio is its use of circulating tumor DNA as a biomarker for assigning patients to experimental...